Johnson & Johnson’s Outlook: Drug Growth, Medical Technology and Strategic Choices

Johnson & Johnson CFO Joe Wolk discusses the company’s raised full-year outlook and the business trends behind it. The interview covers performance across pharmaceuticals and medical technology, as well as the planned separation of the orthopedics business and the company’s approach to pricing and regulation.

■ Business performance and growth drivers
- Pharmaceutical areas, including oncology, neuroscience and immunology, and the launch and uptake of psoriasis treatments
- Medical technology growth, with discussion of a heart pump study and geopolitical and economic factors

■ Strategy and industry environment
- Options for separating the orthopedics business, including the rationale for a spin-off
- Drug pricing, FDA changes and the factors reflected in the company’s outlook

For investors and readers following the pharmaceutical and medical technology sectors, the conversation offers a concise overview of Johnson & Johnson’s stated priorities and operating context. Viewers can use it as background when reviewing future company updates, without treating the interview as investment advice.